𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma

✍ Scribed by F. Cavalli; A. Goldhirsch; P. Siegenthaler; S. Kaplan; M. Beer

Book ID
113146533
Publisher
Elsevier Science
Year
1980
Weight
313 KB
Volume
16
Category
Article
ISSN
0014-2964

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of tiazofurin (NSC 286193
Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma
✍ Paul Y. Holoye; David T. Carr; Hari M. Dhingra; Bonnie S. Glisson; Jin S. Lee; W πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 115 KB

Fourteen evaluable patients with small cell bronchogenic carcinoma received tiazofurin, an inhibitor of inosine monophosphate dehydrogenase, that progressed after one combination chemotherapy. No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days. Toxicity was moderat

Phase II trial of 4β€² deoxydoxorubicin (D
Phase II trial of 4β€² deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma
✍ Christopher Rose; Thomas E. Lad; Lary J. Kilton; Joel Schor; Steven T. Rosen; Ar πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 162 KB

A phase II trial of 4' Deoxydoxorubicin (DXDX) was conducted in unresectable previously untreated non-small cell lung cancer patients. DXDX was administered every 3 weeks by short intravenous infusion at a starting dose of 30 mg/m2, with dose escalation to 40 mg/m2 toxicity permitting. Four response